KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Mixed-methods study to develop extensions to the SPIRIT and CONSORT statements for factorial randomised trials: the Reporting Factorial Trials (RAFT) study. PMID 39961717 · BMJ Open · 2025-Feb-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Opioid-free versus opioid-based anaesthesia for free-flap reconstruction surgery of the breast: protocol for a phase III, multicentre, randomised controlled study. PMID 39961716 · BMJ Open · 2025-Feb-17 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. PMID 39956849 · Signal Transduct Target Ther · 2025-Feb-17 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 3 Panel · risk unclear
Immunotherapy Combined with Chemotherapy in the First-Line Treatment of Advanced Gastric Cancer: Systematic Review and Bayesian Network Meta-Analysis Based on Specific PD-L1 CPS. PMID 39996912 · Curr Oncol · 2025-Feb-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. PMID 40006738 · Vaccines (Basel) · 2025-Feb-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. PMID 39945223 · Cancer · 2025-Feb-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505. PMID 39932777 · Cancer · 2025-Feb-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. PMID 39921852 · Cancer · 2025-Feb-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing? PMID 39913282 · Cancer · 2025-Feb-15 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn's disease. PMID 39954670 · Med · 2025-Feb-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. PMID 39953210 · Support Care Cancer · 2025-Feb-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial. PMID 39952926 · Nat Commun · 2025-Feb-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial. PMID 39419035 · Med · 2025-Feb-14 The record describes an exploratory analysis (correlation of PSA and survival) from the CHART trial, which is a randomized controlled trial in metastatic hormone-sensitive prostate cancer. While it is oncology, human, randomized, drug-intervention, and reports time-to-event efficacy data, the phase of the trial is not explicitly stated in the provided metadata. The deterministic review also flagged 'phase3_evidence_unclear'. Therefore, the phase criterion cannot be definitively established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma. PMID 39395411 · Med · 2025-Feb-14 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis. PMID 39368474 · Med · 2025-Feb-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency. PMID 40005002 · Nutrients · 2025-Feb-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
TREOCAPA: prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen-statistical analysis plan for the randomized phase III group sequential trial. PMID 39948605 · Trials · 2025-Feb-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial. PMID 39948076 · Sci Rep · 2025-Feb-13 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants. PMID 39699245 · Antimicrob Agents Chemother · 2025-Feb-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Colchicine in Acute Myocardial Infarction. PMID 39555823 · N Engl J Med · 2025-Feb-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Routine Spironolactone in Acute Myocardial Infarction. PMID 39555814 · N Engl J Med · 2025-Feb-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. PMID 39282913 · N Engl J Med · 2025-Feb-13 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 2 Figure · 2 Panel · risk unclear
[Heat-sensitive moxibustion assisted in palliative treatment to improve the quality of life in elderly patients with malignant tumor: a randomized controlled trial]. PMID 39943757 · Zhongguo Zhen Jiu · 2025-Feb-12 The study is an oncology randomized controlled trial with original results, but it is excluded because it does not meet key eligibility criteria: the trial phase is not stated (cannot confirm Phase III/IIIb or Phase II/III), the intervention is non-drug (moxibustion), and the primary efficacy endpoint is quality of life, not a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Targeted oxygenation in the respiratory care of premature infants at delivery-effects on outcome: a randomised controlled trial (Torpido 3060) study protocol. PMID 39939099 · BMJ Paediatr Open · 2025-Feb-12 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Overall Survival Following Interval Complete Gross Resection of Advanced Ovarian Cancer via Laparoscopy Versus Open Surgery: An Analysis of the National Cancer Database. PMID 40004693 · J Clin Med · 2025-Feb-11 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 2 Figure · 4 Panel · risk not_visible
Dexamethasone as an adjuvant with ropivacaine in thoracoscopy guided thoracic paravertebral block for postoperative analgesia in thoracic surgery. PMID 39934398 · Sci Rep · 2025-Feb-11 The study is a randomized trial in thoracic surgery patients with lung cancer, but it is not a definitive (Phase III/IIIb or Phase II/III) oncology trial. The intervention is an analgesic adjuvant (dexamethasone with ropivacaine) for postoperative pain management, not a systemic anticancer drug. The endpoints are postoperative pain scores, analgesic consumption, and recovery metrics, not time-to-event oncology efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protocol for a randomised phase 3 trial evaluating the role of Finasteride in Active Surveillance for men with low and intermediate-risk prostate cancer: the FINESSE Study. PMID 39933820 · BMJ Open · 2025-Feb-11 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects. PMID 39928714 · Circulation · 2025-Feb-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping. PMID 39933898 · Cancer Cell · 2025-Feb-10 The record describes a biomarker/subgroup analysis from a Phase III randomized trial (Penelope-B) but does not report the trial's primary or secondary time-to-event efficacy results for the drug intervention. It focuses on molecular heterogeneity and prognosis, not on evaluating the efficacy of the therapeutic intervention itself.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II). PMID 39930784 · Acta Oncol · 2025-Feb-10 The record describes a health-related quality of life and cost analysis from a randomized Phase III melanoma trial (MSLT-II). However, the intervention is a surgical procedure (complete lymph node dissection), not a drug-containing intervention. The primary endpoint is health-related quality of life, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the eligibility criteria for a drug-containing oncology trial with a time-to-event primary/key secondary endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma. PMID 39929517 · BMJ Open · 2025-Feb-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. PMID 39671534 · J Clin Oncol · 2025-Feb-10 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 2 Figure · 6 Panel · risk unclear
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL. PMID 39531610 · J Clin Oncol · 2025-Feb-10 The record meets most criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result) but the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata. Therefore, the 'phase3_or_definitive' criterion cannot be set to true, making the overall eligibility false.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). PMID 39442070 · J Clin Oncol · 2025-Feb-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. PMID 39423355 · J Clin Oncol · 2025-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer. PMID 39378393 · J Clin Oncol · 2025-Feb-10 The study is an oncology randomized trial reporting original results, but it is a Phase II trial (not Phase III/IIIb or definitive Phase II/III), does not involve a drug intervention (only radiation therapy), and does not have a primary or key secondary time-to-event efficacy endpoint (primary endpoint is adverse cosmesis; secondary endpoints include toxicity, not OS/PFS/DFS/EFS/RFS/TTP).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic radiosurgery for 1-10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial. PMID 39340439 · Neuro Oncol · 2025-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Targeting Amyloid Pathology in Early Alzheimer's: The Promise of Donanemab-Azbt. PMID 39998021 · Pharmacy (Basel) · 2025-Feb-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis. PMID 39380152 · Eur Heart J Cardiovasc Pharmacother · 2025-Feb-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Online Radiotherapy: The Paradigm Shift to Real-Time Adaptive Radiotherapy. PMID 39705230 · Dtsch Arztebl Int · 2025-Feb-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer. PMID 39915736 · BMC Cancer · 2025-Feb-06 The record is an ancillary analysis of a Phase III trial evaluating a diagnostic tracer (mitoxantrone hydrochloride) for sentinel lymph node detection in breast cancer. It meets criteria for oncology, human, Phase III, drug intervention, and original result. However, it lacks any time-to-event efficacy endpoint (OS, PFS, DFS, etc.), is not described as randomized, and is a secondary analysis rather than a primary efficacy report. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial. PMID 39915735 · BMC Cancer · 2025-Feb-06 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study. PMID 39912344 · Oncologist · 2025-Feb-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China. PMID 39729925 · Vaccine · 2025-Feb-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists. PMID 39592207 · Gut · 2025-Feb-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Atrasentan in Patients with IgA Nephropathy. PMID 39460694 · N Engl J Med · 2025-Feb-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. PMID 39453772 · N Engl J Med · 2025-Feb-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma. PMID 39401002 · Oncologist · 2025-Feb-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study. PMID 39265970 · Oncologist · 2025-Feb-06 The record is an original, prospective, single-arm Phase II trial of a drug (fosnetupitant). It is human and oncology. However, it is excluded because it is non-randomized, not a Phase III/IIIb or Phase II/III trial, and its primary and secondary endpoints are safety measures and complete response rate, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. PMID 39258838 · N Engl J Med · 2025-Feb-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -